Advertisement

Topics

Eli Lilly: Lasmiditan Meets Primary Endpoint In Second Phase 3 Study

07:15 EDT 4 Aug 2017 | FinanzNachrichten

INDIANAPOLIS (dpa-AFX) - Eli Lilly and Company (LLY) announced that lasmiditan, an investigational molecule for the acute treatment of migraine, met its primary endpoint in SPARTAN, a second Phase...

Original Article: Eli Lilly: Lasmiditan Meets Primary Endpoint In Second Phase 3 Study

NEXT ARTICLE

More From BioPortfolio on "Eli Lilly: Lasmiditan Meets Primary Endpoint In Second Phase 3 Study"

Quick Search
Advertisement
 

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...